LSL Pharma Group Inc. shows modest gains this week amid positive revenue reports and strategic acquisitions.
This week, LSL Pharma Group Inc. (LSL.V) saw its stock price increase by 1.54%, closing at C$0.33. The company has been in the spotlight due to recent announcements regarding record revenues and acquisitions, which may signal potential growth in its operational segments.
Advertisement
LSL Pharma Group Inc.
LSL.V
LSL.V
LSL Pharma Group Inc.
WealthAwesomeMarket cap
$38.02M
52W high
$0.56
52W low
$0.28
1W change
+0.00%
Beta
-0.40
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LSL's historical volatility
30-Day Vol
47.5%
Annualized
90-Day Vol
50.5%
Annualized
Trend (90d)
-33.6%
Annualized drift
90d Mean
C$0.27
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.29 | C$0.24 – C$0.34 |
| 60 trading days | C$0.28 | C$0.22 – C$0.35 |
| 90 trading days | C$0.27 | C$0.20 – C$0.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: While LSL Pharma Group Inc. has reported strong revenue growth and completed significant acquisitions, investors should remain cautious due to its ongoing negative profit margins and the impact of market conditions on its stock price.
LSL Pharma Group Inc. Reports Record Revenues Amid Recent Acquisitions
The company reported record quarterly revenues of $7.6 million for Q3-2025, marking a 62% increase year-over-year, alongside the acquisition of Juno OTC, positioning it for further growth.
Bull case
LSL Pharma Group has recently posted record revenues for Q2-2026 and completed an acquisition that enhances its product offerings. This suggests that the company is on a growth path and may continue to expand its market presence.
Bear case
Despite the positive revenue reports, LSL Pharma Group is still operating at a loss, with a profit margin of -17.5%. This ongoing loss may deter risk-averse investors from getting involved with the stock.
Recent Price Action
Advertisement
LSL Pharma Group Inc. closed at C$0.33, reflecting a 1.54% increase over the week. However, the stock has decreased by 7.04% over the past month and is down 5.71% year-to-date.
Catalysts for Price Movement
This week's positive price action can be attributed to recent announcements from LSL Pharma Group, including record revenues for Q2-2026 and the completion of the acquisition of Juno OTC Inc. for $5 million. This acquisition is expected to expand its over-the-counter product offerings, reinforcing investor sentiment despite the company’s ongoing challenges.
Technical Picture
Currently, LSL Pharma Group is trading near its 50-day moving average of C$0.34, indicating a slight bearish trend as the stock is down 3.3% from this average. The 200-day moving average stands at C$0.39, suggesting a more pronounced bearish trend, with the stock down 14.3% from this level. The 52-week range for LSL.V is C$0.30 to C$0.56, placing the current price at approximately 12% of this range. The stock has a beta of -0.52, indicating lower volatility compared to the market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
